Loading…
Cytosorbents Corporation is projected to rise to $0.3971 by 2027, a +5% move from its current price of $0.3774. CTSO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/5/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 6 | $0.3641 | $0.3775 | $0.3914 | +0.02% |
| Aug 7 | $0.3587 | $0.3776 | $0.3974 | +0.05% |
| Aug 8 | $0.3547 | $0.3777 | $0.4021 | +0.07% |
| Aug 9 | $0.3514 | $0.3778 | $0.4062 | +0.10% |
| Aug 10 | $0.3485 | $0.3779 | $0.4098 | +0.12% |
| Aug 11 | $0.3459 | $0.378 | $0.413 | +0.15% |
| Aug 12 | $0.3435 | $0.3781 | $0.4161 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3435 | $0.3781 | $0.4161 | +0.17% |
| Week 2 | $0.3307 | $0.3787 | $0.4337 | +0.35% |
| Week 3 | $0.3213 | $0.3794 | $0.4479 | +0.53% |
| Week 4 | $0.3137 | $0.38 | $0.4604 | +0.70% |
| Week 5 | $0.3073 | $0.3807 | $0.4717 | +0.88% |
| Week 6 | $0.3016 | $0.3814 | $0.4823 | +1.05% |
| Week 7 | $0.2965 | $0.382 | $0.4924 | +1.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cytosorbents Corporation is a healthcare company focusing on the research, development, and commercialization of medical devices with its blood purification technology platform.
Its flagship CytoSorb is an extracorporeal blood purification cartridge designed to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications; it also aims to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
The company was founded in 1997 and is headquartered in Princeton, New Jersey. Cytosorbents Corporation was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010.
CTSO is currently trading at $0.3614 with a market cap of $22.71M, and it ranks 4743 by market capitalization.
The near-term outlook shows a flat horizon, with 2026 forecast indicating an average price of $0.3614 and ROI of 0%, alongside a min of $0.36 and a max of $0.4631. The sentiment for 2026 is NEUTRAL.
Looking further out, the forecast envisions a bullish path from 2028 onward, with rising averages and higher ROI into 2050. Notable milestones include 2028 avg $0.4463 (ROI 23.5%), 2029 avg $0.5154 (ROI 42.6%), 2030 avg $0.4914 (ROI 36%), 2040 avg $0.6788 (ROI 87.8%), and 2050 avg $1.41 (ROI 289.4%).
A major floor 24.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.3% below — buyers have tended to step in here.
The nearest ceiling, 23.7% above — a clean break opens room to run.
A major ceiling 74.9% above — clearing it would confirm fresh momentum.
Key CTSO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTSO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3684 | Buy | $0.3735 | Buy |
| MA 10 | $0.3647 | Buy | $0.3709 | Buy |
| MA 20 | $0.3721 | Buy | $0.3774 | Buy |
| MA 50 | $0.4113 | Sell | $0.4192 | Sell |
| MA 100 | $0.5054 | Sell | $0.4905 | Sell |
| MA 200 | $0.6089 | Sell | $0.602 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.13 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 84.44 | Neutral |
| Williams %R (14) | -18.41 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 1.55 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 81.59 | Sell |
| TRIX (15) | -0.61 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 61.67 | Neutral |
| Momentum (10) | 0.00 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.38 | Buy |
| ADX (14) | 14.15 | Neutral |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is NEUTRAL. The RSI14 sits at 40, and the moving averages are positioned with the SMA50 at $0.4364 and the SMA200 at $0.6344.
Support is at $0.36 and resistance at $0.519, framing a trading backdrop near the current level. The 30-day price range runs from $0.2697 to $0.4843, highlighting limited momentum in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.35 | $0.3774 | $0.4705 | 0% | Neutral | |
| $0.3074 | $0.3971 | $0.5476 | +5% | Neutral | |
| $0.369 | $0.4956 | $0.7169 | +31% | Bullish | |
| $0.3907 | $0.5419 | $0.8134 | +44% | Bullish | |
| $0.3737 | $0.5335 | $0.8257 | +41% | Bullish | |
| $0.3781 | $0.5543 | $0.8809 | +47% | Bullish | |
| $0.3511 | $0.5276 | $0.8587 | +40% | Bullish | |
| $0.3506 | $0.5393 | $0.8967 | +43% | Bullish | |
| $0.4033 | $0.6344 | $1.08 | +68% | Bullish | |
| $0.4516 | $0.7258 | $1.25 | +92% | Bullish | |
| $0.4729 | $0.8395 | $1.56 | +122% | Bullish | |
| $0.7676 | $1.63 | $3.38 | +332% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.35 | $0.3774 | $0.4468 | +0.00% |
| September 2026 | $0.319 | $0.3806 | $0.4691 | +0.84% |
| October 2026 | $0.3206 | $0.3861 | $0.4828 | +1.45% |
| November 2026 | $0.3047 | $0.3697 | $0.4675 | -4.25% |
| December 2026 | $0.3014 | $0.3683 | $0.4705 | -0.38% |
Click any year to see its month-by-month CTSO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CTSO could reach as high as $0.4705, with a base case around $0.3774 and support toward $0.35 — roughly 0% from $0.3774. Price action looks broadly range-bound.
Expect CTSO to range from $0.3074 to $0.5476 through 2027. The $0.3971 average target implies a +5% move from current prices. That is up +5% on the projected 2026 average. A consolidation phase looks the most probable path here.
The CTSO price prediction for 2028 points to an average of $0.4956 (low $0.369, high $0.7169) — a potential gain of +31% on today's $0.3774. Momentum favours further upside here.
In 2029, CTSO is projected to trade between $0.3907 and $0.8134, averaging $0.5419 — a potential gain of +44% from today's $0.3774. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Cytosorbents Corporation's 2030 outlook centres on $0.5335, within a $0.3737 to $0.8257 range. That is -2% versus the projected 2029 average. That marks a +41% change versus current levels. Momentum favours further upside here.
By 2031, CTSO could reach as high as $0.8809, with a base case around $0.5543 and support toward $0.3781 — roughly +47% from $0.3774. Buyers look set to stay in control over this stretch.
Expect CTSO to range from $0.3511 to $0.8587 through 2032. The $0.5276 average target implies a +40% move from current prices. That is -5% versus the projected 2031 average. Momentum favours further upside here.
The CTSO price prediction for 2033 points to an average of $0.5393 (low $0.3506, high $0.8967) — a potential gain of +43% on today's $0.3774. Buyers look set to stay in control over this stretch.
In 2034, CTSO is projected to trade between $0.4033 and $1.08, averaging $0.6344 — a potential gain of +68% from today's $0.3774. That is up +18% on the projected 2033 average. Momentum favours further upside here.
Cytosorbents Corporation's 2035 outlook centres on $0.7258, within a $0.4516 to $1.25 range. That is up +14% on the projected 2034 average. That marks a +92% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CTSO could reach as high as $1.56, with a base case around $0.8395 and support toward $0.4729 — roughly +122% from $0.3774. Momentum favours further upside here.
Expect CTSO to range from $0.7676 to $3.38 through 2050. The $1.63 average target implies a +332% move from current prices. That is up +94% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CTSO today (≈ 2,649.708532 CTSO) could be worth
$4,319.58
+$3,319.58 (+332%) by 2050 · US Dollar
Based on the average projected CTSO price of $1.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTSOwould be worth at today's price.
$1,000 invested in CTSO on Aug 5, 2025 (≈ 1,092.896149 CTSO) would be worth
$412.46
-$587.54 (-58.8%) today · 0.41× · US Dollar
Based on a CTSO entry price of $0.915 vs. today's $0.3774.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.354 | $1,066.1 | +6.6% |
| 1 month ago | $0.43 | $877.67 | -12.2% |
| 3 months ago | $0.61 | $618.69 | -38.1% |
| 6 months ago | $0.672 | $561.61 | -43.8% |
| 1 year ago | $0.915 | $412.46 | -58.8% |
| All time (5.0y) ago | $7.78 | $48.51 | -95.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTSO forecast.
Our base-case forecast reaches $0.75 around 2040.
Implied market cap at $0.75: $47.13M
The multi-year forecast shows a bullish trajectory for Cytosorbents, with gradual price appreciation and rising confidence over time. In 2030, the model projects an average price of $0.4914, a min of $0.325 and a max of $0.8043, for a 36% return. The 2040 forecast strengthens to an average of $0.6788, with a max of $1.37 and an 87.8% return.
By 2050, the average is $1.41 and the max is $3.21, implying a 289.4% return. The sentiment is bullish for 2028 and beyond, with the years in between showing continued upward momentum, though these are estimates and not guarantees and carry risk.
Tap a question to reveal the answer.
2030 avg $0.4914; min $0.325; max $0.8043; ROI 36%.
The forecast shows bullish sentiment in 2028-2050 with avg rising to $1.41 by 2050 and ROI up to 289.4%; 2026 is NEUTRAL.
2035 min $0.3691; avg $0.6523; max $1.21; ROI 80.5%. 2050 max $3.21; avg $1.41; ROI 289.4%.
Current price $0.3614; Market cap $22.71M.
RSI14 40; SMA50 $0.4364; SMA200 $0.6344; Support $0.36; Resistance $0.519; 30-day range $0.2697–$0.4843; Sentiment NEUTRAL.
Cytosorbents Corporation Community Discussion
0Share your Cytosorbents Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.